Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models

Diabetes

Volumn 62, Issue 1, 2013, Pages 261-272

  Chen, Ying ^a,b   Hu, Yang ^a,b   Lin, Mingkai ^a,b,c   Jenkins, Alicia J ^b,d   Keech, Anthony C ^e   Mott, Robert ^a   Lyons, Timothy J ^b   Ma, Jian Xing ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; OXYGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM CELL; GENE OVEREXPRESSION; INSULIN DEPENDENT DIABETES MELLITUS; KNOCKOUT MOUSE; LEUKOSTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION; STREPTOZOCIN DIABETES;

ANIMALS; CAPILLARY PERMEABILITY; CELL ADHESION; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; FENOFIBRATE; HYPOGLYCEMIC AGENTS; LEUKOCYTES; MALE; MICE; MICE, INBRED C57BL; PPAR ALPHA; RATS; RATS, INBRED BN; RETINA;

EID: 84872016068     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-0413     Document Type: Article

References (50)

1. Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. Int J Clin Pract 2006;60:1471-1483
2. Blonde L. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve Clin J Med 2009;76(Suppl. 5):S4-S11
3. Fong DS, Sharza M, Chen W, Paschal JF, Ariyasu RG, Lee PP. Vision loss among diabetics in a group model Health Maintenance Organization (HMO). Am J Ophthalmol 2002;133:236-241
4. Do carmo A, Ramos P, Reis A, Proença R, Cunha-vaz JG. Breakdown of the inner and outer blood retinal barrier in streptozotocin-induced diabetes. Exp Eye Res 1998;67:569-575
5. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002;47(Suppl. 2):S253-S262
6. Sheth JJ. Diabetes, microalbuminuria and hypertension. Clin Exp Hypertens 1999;21:61-68
7. Shiels IA, Zhang S, Ambler J, Taylor SM. Vascular leakage stimulates phenotype alteration in ocular cells, contributing to the pathology of proliferative vitreoretinopathy. Med Hypotheses 1998;50:113-117
8. Stitt AW, Bhaduri T, McMullen CB, Gardiner TA, Archer DB. Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol Cell Biol Res Commun 2000;3:380-388
9. Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 2003;115(Suppl. 8A):24S-28S
10. Orchard TJ. Dyslipoproteinemia and diabetes. Endocrinol Metab Clin North Am 1990;19:361-380
11. Wilkinson-Berka JL, Miller AG. Update on the treatment of diabetic retinopathy. ScientificWorldJournal 2008;8:98-120
12. Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010;248:915-930
13. Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH. Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci 2001;42:1586-1591
14. Esser P, Bresgen M, Fischbach R, Heimann K, Wiedemann P. Intercellular adhesion molecule-1 levels in plasma and vitreous from patients with vitreoretinal disorders. Ger J Ophthalmol 1995;4:269-274
15. Roestenberg P, van Nieuwenhoven FA, Wieten L, et al. Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care 2004;27:1164-1170
16. Drouin P, Méjean L, Lambert D, Sauvanet JP, Debry G. Effect of procetofen on the lipoprotein profile in patients with type II hyperlipoproteinemia. Med Welt 1979;30:1910-1913 [in German]
17. Micheli H, Pometta D, Gustafson A. Treatment of hyperlipoproteinemia (HLP) type II A with a new phenoxy-isobuturic acid derivative, procetofen. Int J Clin Pharmacol Biopharm 1979;17:503-506
18. Kraja AT, Province MA, Straka RJ, Ordovas JM, Borecki IB, Arnett DK. Fenofibrate and metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2010;10:138-148
19. Drouin P, Lambert D, Mejean L, Pointel JP, Debry G. Study of lipid metabolic coefficient K2 in patients with hyperlipoproteinemia type IV before and after reduction of triglyceride level by adapted diet therapy. Nutr Metab 1979;23:416-428 [in French]
20. Meissner M, Berlinski B, Gille J, Doll M, Kaufmann R. Peroxisome proliferator activated receptor-α agonists suppress transforming growth factor-α-induced matrix metalloproteinase-9 expression in human keratinocytes. Clin Exp Dermatol 2011;36:911-914
21. Garrido-Urbani S, Jemelin S, Deffert C, et al. Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism. PLoS ONE 2011;6:e14665
22. Price ET, Welder GJ, Zineh I. Modulatory effect of fenofibrate on endothelial production of neutrophil chemokines IL-8 and ENA-78. Cardiovasc Drugs Ther 2012;26:95-99
23. Elijah IE, Børsheim E, Maybauer DM, Finnerty CC, Herndon DN, Maybauer MO. Role of the PPAR-α agonist fenofibrate in severe pediatric burn. Burns 2012;38:481-486
24. Miranda S, González-Rodríguez A, García- Ramírez M, et al. Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions. J Cell Physiol 2012;227:2352-2362
25. Trudeau K, Roy S, Guo W, et al. Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability. Invest Ophthalmol Vis Sci 2011;52:6348-6354
26. Villarroel M, Garcia-Ramírez M, Corraliza L, Hernández C, Simó R. Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation. Diabetologia 2011;54:1543-1553
27. Simó R, Hernández C. Advances in the medical treatment of diabetic retinopathy. Diabetes Care 2009;32:1556-1562
28. Simó R, Hernández C. Fenofibrate in the treatment of diabetic retinopathy. Med Clin (Barc) 2008;131:16-17 [in Spanish]
29. Simó R, Hernández C. Fenofibrate for diabetic retinopathy. Lancet 2007;370:1667-1668
30. Keech AC, Mitchell P, Summanen PA, et al.; FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-1697
31. Davis TM, Ting R, Best JD, et al.; Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011;54:280-290
32. Rajamani K, Colman PG, Li LP, et al.; FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009;373:1780-1788
33. Chew EY, Ambrosius WT, Davis MD, et al.; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-244
34. Sharma SK, Babitch JA. Application of Bradford ' s protein assay to chick brain subcellular fractions. J Biochem Biophys Methods 1980;2:247-250
35. Chen Y, Moiseyev G, Takahashi Y, Ma JX. Impacts of two point mutations of RPE65 from Leber's congenital amaurosis on the stability, subcellular localization and isomerohydrolase activity of RPE65. FEBS Lett 2006;580:4200-4204
36. Ricci B. Oxygen-induced retinopathy in the rat model. Doc Ophthalmol 1990;74:171-177
37. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994;35:101-111
38. Chen Y, Hu Y, Zhou T, et al. Activation of the Wnt pathway plays a pathogenic role in diabetic retinopathy in humans and animal models. Am J Pathol 2009;175:2676-2685
39. Zhang SX, Sima J, Shao C, et al. Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes. Diabetologia 2004;47:124-131
40. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003;44:2155-2162
41. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 2005;112:806-816
42. Hahn SE, Goldberg DM. Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate. Biochem Pharmacol 1992;43:625-633
43. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007;2007:95103
44. Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 2004;13:1275-1293
45. Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenzi M. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 2002;51:2241-2248
46. Vinores SA, Xiao WH, Aslam S, et al. Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol 2006;206:749-758
47. Dorne PA. Exudative diabetic retinopathy. The use of clofibrate in the treatment of hard exudates using a reduced but prolonged dosage over several years (author's transl). Arch Ophtalmol (Paris) 1977;37:393-400 [in French]
48. Burgess DC, Hunt D, Li L, et al. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart J 2010;31:92-99
49. Hiukka A, Maranghi M, Matikainen N, Taskinen MR. PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol 2010;6:454-463
50. Sanders RJ, Wilson MR. Diabetes-related eye disorders. J Natl Med Assoc 1993;85:104-108